ARGX vs. BMRN: argenx vs. BioMarin Pharmaceutical Stock Comparison
How do argenx (ARGX) and BioMarin Pharmaceutical (BMRN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
argenx (ARGX) and BioMarin Pharmaceutical (BMRN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
BioMarin Pharmaceutical (BMRN) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ARGX | BMRN |
|---|---|---|
| Name | argenx SE American Depositary Receipt | BioMarin Pharmaceutical Inc. |
| Country/Region | Netherlands | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 58.31 billion USD | 10.85 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 18, 2017 | July 26, 1999 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ARGX | BMRN |
|---|---|---|
| Total Return (1Y) | 11.91% | 8.82% |
| Total Return (3Y, Annualized) | 25.68% | -12.54% |
| Total Return (5Y, Annualized) | 24.22% | -7.51% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ARGX | BMRN |
|---|---|---|
| Volatility (1Y, Annualized) | 37.87% | 35.50% |
| Beta (5Y) | 0.45 | 0.24 |
| Max Drawdown (5Y) | -38.20% | -57.64% |
| Avg. Volume (3M) | 359.84K | 2.28M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ARGX | BMRN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 0.13 |
| Sortino Ratio (1Y) | 0.31 | 0.23 |
Profitability
ROE (TTM)
argenx (ARGX) has no ROE value reported for this period; BioMarin Pharmaceutical (BMRN) reports a negative figure of -0.31%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ARGX
- --
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile argenx (ARGX) reports 31.73%, ranking against industry peers normally.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.73%
- ARGX
- 31.73%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both argenx (ARGX) at 36.27% and BioMarin Pharmaceutical (BMRN) at 26.58% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.27%
- Max
- 83.12%
- ARGX
- 36.27%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ARGX | BMRN |
|---|---|---|
| ROE (TTM) | -- | -0.31% |
| ROA (TTM) | -- | 3.89% |
| Net Margin (TTM) | 31.73% | -0.52% |
| Operating Margin (TTM) | 36.27% | 26.58% |
| Gross Margin (TTM) | 59.84% | 53.21% |
Growth
Revenue Growth
argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while BioMarin Pharmaceutical (BMRN) at 12.87% is closer to the peer norm — faster top-line expansion for ARGX.
EPS Growth
Both argenx (ARGX) at 53.13% and BioMarin Pharmaceutical (BMRN) at -18.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | ARGX | BMRN |
|---|---|---|
| Revenue Growth (YoY) | 89.64% | 12.87% |
| Revenue Growth (3Y CAGR) | 116.25% | 15.40% |
| EPS Growth (YoY) | 53.13% | -18.55% |
| EPS Growth (3Y CAGR) | -- | 33.89% |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: BioMarin Pharmaceutical (BMRN) shows current ratio of 2.44 against its industry benchmark, while argenx (ARGX) has no reading this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ARGX
- --
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
Debt / Equity (MRQ)
argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while BioMarin Pharmaceutical (BMRN) at 0.67 sits in the higher-leverage quartile.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- ARGX
- 0.01
- Min
- 0.00
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ARGX | BMRN |
|---|---|---|
| Current Ratio (MRQ) | -- | 2.44 |
| Debt / Equity (MRQ) | 0.01 | 0.67 |
| Net Debt / EBITDA | -2.70 | 4.04 |
Dividends
Dividend Yield (TTM)
Neither argenx (ARGX) nor BioMarin Pharmaceutical (BMRN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither argenx (ARGX) nor BioMarin Pharmaceutical (BMRN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ARGX | BMRN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.12
- Max
- 85.34
- Q3
- 43.46
- ARGX
- 32.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while argenx (ARGX) at 9.86 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.86
- Max
- 58.18
- Q3
- 25.77
- ARGX
- 9.86
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
P/B Ratio (MRQ)
BioMarin Pharmaceutical (BMRN) at 1.73 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
172.23
- ARGX
- 172.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ARGX | BMRN |
|---|---|---|
| P/E Ratio (TTM) | 32.12 | -- |
| P/S Ratio (TTM) | 9.86 | 2.97 |
| P/B Ratio (MRQ) | 172.23 | 1.73 |
| Free Cash Flow Yield (TTM) | -- | -0.15% |